INTRODUCTION
Pexiganan (or MSI-78) is a 22-amino acid linear analog of magainin-2, a natural antimicrobial peptide isolated from the skin of the African clawed frog, Xenopus laevis. [1] [2] [3] Pexiganan is remarkably effective against more than 3,000 species of gram-positive and gram-negative bacteria that cause infections on skin and soft tissues, including methicillinresistant Staphylococcus aureus (MRSA), and has no propensity to induce bacterial resistance. In two phase III clinical trials involving 835 patients with infected diabetic foot ulcers, both topical pexiganan acetate 1% and oral ofloxacin (800 mg=day) achieved clinical cure or improvement in 90% of patients, so it rapidly underwent commercial development for topical application as a cream (pexiganan acetate 1%). [4] However, in 1990, the U.S. Food and Drug Administration denied its approval on the basis that its effectiveness in completely eradicating the pathogen (66% of treated patients) was not higher than that achieved by ofloxacin taken orally (82% of treated patients), [5] which led the industrial developer (Genaera Corporation, formerly Magainin Pharmaceutical Inc.) to abandon the production of pexiganan acetate. Even so, the very large and growing incidence of diabetes in northwestern countries, together with the lack of valuable topical antimicrobials to treat infected diabetic foot ulcers and the well-known problems associated with oral drug delivery, makes further exploration of pexiganan-based systems worthwhile, explaining the recent (October 2007) acquisition by the U.S. pharmaceutical corporation MacroChem of the exclusive option to license pexiganan worldwide. [6] This was followed by the latest (as of 13 March 2008) press release on new phase III clinical trials promoted by this company that confirm the efficacy of pexiganan to be statistically equivalent to that of oral antibiotic therapy. [7] Taking advantage of our prior experience in the synthesis and study of antimicrobial peptides, [8] [9] [10] as well as in the development of novel chitosan-based biopolymers for biomedical applications, [11] [12] [13] we decided to break through to the preparation of a novel chitosan-pexiganan conjugate with potential application in the topical treatment of infected diabetic foot ulcers. We hope such a conjugate will combine the excellent antimicrobial properties of pexiganan with the well-known biocompatibility and skin-injury-healing ability of chitosan. Chitosan-based materials have been used for several biomedical purposes, including drug delivery, vascular grafts, cartilage regeneration, sutures, and woundhealing materials, because among chitosan's most appealing characteristics are its bioadhesive and self-aggregation properties, as well as its ability to enhance cell proliferation, thus promoting tissue regeneration. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] In 2004, Gopinath et al. reported pexiganan-incorporated collagen matrices that led to improvement of tissue reconstruction in infected wounds in mice as compared to collagen films alone. [26] However, so far nothing has been attempted concerning the development of 
MATERIALS AND METHODS

Instrumentation
FT-IR spectra were recorded from KBr pellets of pexiganan and pexiganan-chitosan on a Jasco FT=IR-460 instrument (each spectrum, run in duplicate, was obtained from 32 scans between 4000 and 400 cm À1 at a resolution of 4 cm À1 ). AAA of peptide and peptide-chitosan hydrolysates was carried out on a Beckman 6300 amino acid analyzer. Mass spectra (MS) were obtained by the matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) technique on a MALDI-TOF Voyager DE Perspective spectrometer from Applied Biosystems. High-performance liquid chromatographic (HPLC) analyses were run on an analytical Beckman System Gold, and peptide purification was carried out on a preparative HPLC Waters DeltaPrep
4000 system, using C-18 reverse-phase columns. Peptide and peptidechitosan conjugate were freeze-dried on a Christ alpha l-4 lyophilizer.
Peptide Synthesis
Pexiganan-Ala-Ala-Cys amide (Gly-Ile-Gly-Lys-Phe-Leu-Lys-Ala-LysLys-Phe-Gly-Lys-Ala-Phe-Val-Lys-Ile-Leu-Lys-Lys-Ala-Ala-Cys-NH 2 ; molecular weight, 2721 Da) was synthesized manually on a Fmoc-Rink-MBHA resin by standard Fmoc=tBu solid-phase peptide synthesis (SPPS) strategies. [8, 9] The target peptide was isolated from the crude mixture by preparative HPLC and characterized by analytical HPLC, AAA, and MALDI-TOF MS (data not shown).
Modification of Chitosan with the Sulfo-EMCS Cross-Linker
Chitosan ($10 mmol -NH 2 groups) was dissolved in acetic acid=sodium acetate buffer at pH 6.0 (1 ml), and phosphate-buffered saline (PBS) buffer (pH 7.4, 5 ml) was added to the solution together with EDTA (5 mmol). The mixture was put under vigorous stirring at 4 C, and Sulfo-EMCS ($70 mmol) was then slowly added to the solution. The reaction was allowed to proceed at 4 C for 30 min and then at room temperature for 90 min. The solution was then dialyzed against PBS over 24 hours (three buffer renewals) and then immediately used in the subsequent reaction.
Attachment of Pexiganan-Ala-Ala-Cys to the Modified Chitosan
The modified chitosan solution, obtained as described in the previous section, was put under vigorous stirring at 4 C. The peptide (3.2 mmol) was then slowly added to the solution, and the reaction was allowed to evolve at 4 C for 30 min and then at room temperature for a further 90 min. The reaction was quenched by addition of free cysteine 100 mM in PBS (1 ml) and further reaction for 15 min at room temperature. The final mixture was dialyzed against PBS (2 days, four buffer renewals) and then against deionized water (3 days, six solvent renewals), after which it was freezedried and characterized by FT-IR.
Analysis of the Peptide and the Peptide-Chitosan Conjugate by AAA
The amount of peptide and its amino acid composition, for both the pure peptide and its chitosan conjugate, were determined by standard AAA Chitosan-Pexiganan Conjugate 1231
procedures. [8, 9] Briefly, a known amount of the sample was submitted to acid hydrolysis in aqueous HCl 6 M containing 1 mM of aminobutyric acid as internal reference. The hydrolysis was carried out in a sealed glass tube at 100 C and over 24 h, for full cleavage of peptide bonds and concomitant quantitative release of the amino acids. The hydrolysate was then evaporated to dryness, and the residue was retaken with a known volume of citric acid=sodium citrate buffer (60 mM, pH 2), of which, after adequate dilutions, a known aliquot was filtered through a nylon filter (Ø ¼ 0.45 mm) and injected into the analyzer.
RESULTS AND DISCUSSION
The preparation of covalent peptide and protein conjugates is often accomplished by means of maleimide-based crosslinkers. [27, 28] Other elegant approaches include enzyme-catalyzed conjugations, such as the preparation of a gelatin-chitosan conjugate through tyrosinase-mediated conversion of Tyr residues into their reactive o-quinone moieties. [29] Recently, Masuko et al. used N-e-maleimidocaproyloxy-sulfosuccinimide ester (Sulfo-EMCS) to promote the attachment of bovine serum albumin (BSA) to thiolated chitosan. [30] Thus, we have investigated whether it was possible to prepare a pexiganan-chitosan conjugate by a similar procedure, but in our case using unmodified chitosan and a pexiganan analog having an additional C-terminal Ala-Ala-Cys segment to provide the peptide the Cys thiol necessary to accomplish the desired reaction (Scheme 1). The target peptide was successfully synthesized and isolated (not shown), and its attachment to unmodified chitosan was then promoted by Sulfo-EMCS, yielding a product that was characterized by FT-IR and AAA.
The FT-IR spectrum of chitosan (Fig. 1a) is characterized by a large and intense band at 3450-3200 cm À1 (hydrogen-bonded O-H stretching and N-H stretching bands, with maximal absorption at 3376 cm À1 ) partially overlapped with C-H stretching bands at $2800 cm À1 ; bands due to the N-acetyl-D-glucosamine (GlcNHAc) units, with amide I (C¼O stretching) at 1645 cm , amide III (CÀN stretching coupled with N-H plane deformation) at 1412 cm À1 and symmetrical angular deformation of -CH 3 at 1384 cm À1 ; C-N stretching of the amino groups at 1325 cm À1 ; O-H plane deformation at 1259 cm À1 ; C-O stretching band at 1078 cm À1 ; C-O-C stretching vibration in the glucopyranose ring at 1030 cm À1 ; and the specific bands of the b(1 ! 4) glycoside bridge at 1153 cm À1 and 899 cm À1 . [12, 13] In comparison, the FT-IR spectrum of the peptide conjugate (Fig. 1b) , while still displaying the characteristic bands due to the polysacharide chains (O-H bending at À1 , C-O stretching at 1079 cm À1 , C-O-C stretching vibration in the glucopyranose ring at 1036 cm À1 and the specific bands of the b(1 ! 4) glycoside bridge at 1153 cm À1 and 899 cm À1 ), it also exhibits significant differences as compared to the spectrum of the parent polymer. For instance, the large and intense O-H þ N-H stretching band has its maximal absorption shifted down to 3289 cm À1 (D ¼ À87 cm À1 ), which certainly reflects the significant contribution from N-H stretching vibrations due to the primary amino groups from the N-terminal amino acid and Lys side-chains (10 groups per peptide chain) and to the amide bonds (25 secondary plus 1 primary amide groups per peptide chain); this interpretation is reinforced by the changes registered in the amide I and amide II bands, whose relative intensities are dramatically changed from one spectrum to the other, as these are the two most intense bands in the spectrum of the peptide-chitosan conjugate, but not in the spectrum of unmodified chitosan. The wavenumbers for the amide I and amide II bands are also different in the conjugate, where they appear at 1653 (D ¼ þ8 cm À1 ) and 1541 cm À1 (D ¼ À16 cm À1 ), respectively. If we go further and take a look at the hyperfine structure of the conjugate's amide I band (inset in 
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Fig. 1b), we find that it reflects the contributions of the different amide bonds present and of peptide secondary structure determinants. In fact, the bands at 1682, 1659, and 1636 cm À1 observed in the present case are close to those reported by Shanmugam et al. for the FT-IR absorption spectrum of pexiganan in methanol, respectively, at 1680, 1659, and 1630 cm À1 , [31] with slight differences probably due to the additional C-terminal Ala-Ala-Cys stretch in our peptide. These authors have analyzed the structure of pexiganan in aqueous and different organic media using FT-IR absorption and other spectroscopic techniques and found that this peptide exhibits conformational polymorphic behavior in different solvents, which is reflected on the wavenumbers associated to peaks in the amide I region. Thus, a comparison of our data with those from these authors would suggest the peptide adopt a dominant b-sheet structure with b-turn and minor a-helix content, when inserted into the chitosan matrix. [31] However, this hypothesis must be regarded with some caution, as our spectra were acquired from KBr pellets, a procedure that has been previously found to change protein structure from a-helix to b-sheet. [32] Additional information on peptide secondary structure within the chitosan matrix can be withdrawn from the amide III region. In fact, among the spectral regions arising out of vibrational modes of amide bonds, amide I and amide III bands are the most sensitive to variations in secondary structure folding. The amide I region from spectra of proteins and peptides suffers from several limitations, including interference with bands from water or hydroxylated solvents, and a relatively unstructured contour due to overlap of orbital bands that arise from various secondary structures; yet, it is still the most commonly used for secondary structure analysis, given its high intensity. In contrast, the corresponding amide III region ($1350-1200 cm À1 ), although fairly weak in intensity, is not affected by these constraints, so it should be preferred to gain reliable information on peptide secondary structure. [32, 33] This region is quite different between both spectra displayed in Figs. 1a and b, attesting the significant alterations brought by peptide insertion. Thus, amide III bands arise at 1356-1306 cm À1 in the peptide conjugate, which, according to Cai and Singh, reflects a predominant peptide a-helical structure. [33] This interpretation follows the opposite direction of that given by the analysis of the amide I region, reinforcing the need to analyze these data with caution, at least concerning peptide secondary structure predictions.
Finally, differences in the C-H stretching region are also noteworthy: in contrast to what is observed in the spectrum of chitosan, the FT-IR spectrum for the peptide conjugate exhibits three perfectly defined bands at 3060, 2950, and 2892 cm À1 , attributed to C-H stretching vibrations in, respectively, aromatic, methylene, and methyl groups, most probably from the side chains of the aromatic amino acid Phe (three per peptide chain) and of aliphatic amino acids such as Leu, Ile, Val, Ala and Lys. C-C (aliphatic and aromatic) stretching vibrations are hindered by amide I and II bands, but a C-C in-ring stretching, typical of aromatics, can still be distinguished at 1458 cm À1 . In view of this, FT-IR data alone definitely support the successful insertion of the peptide into the chitosan matrix. Still, characterization of the peptide-chitosan conjugate by AAA provided the ultimate proof of a profitable attachment of the antimicrobial peptide to the polymer.
Thus, as shown in Table 1 , acid hydrolysis of the product allowed determining the amino acids whose identities and relative proportions fully agree with what was expected from the peptide sequence.
Overall, we established an easy, fast, and profitable method for the covalent attachment of pexiganan to chitosan. An alternative approach would be the synthesis of the peptide as a C-terminal carboxyl and then its attachment to the chitosan's amino groups by means of condensation agents such as a water-soluble carbodiimide, [34] which has been used in polymer chemistry as a cross-linking agent [35] [36] [37] and also to attach other peptides to the chitosan matrix.
[38] However, both the peptide N-terminal a-amine and Lys-side chain e-amino groups would be reactive under those conditions, and extensive cross-linking between peptide chains would most probably occur. To overcome this problem, a fully protected peptide analog, assembled on an acid hyperlabile resin such as 2-chlorotrityl chloride (2-CTC) resin, [39] could be used; but then peptide's solubility in aqueous media would be minimal, so the condensation to chitosan should be carried out in a suitable organic solvent such as DCM. This, in turn, would require the conversion of chitosan (insoluble in current organic media) into a suitable organic-soluble derivative, such as Otrityl-chitosan. [40] [41] [42] [43] Taken together, these considerations show that our route for peptide insertion into the polymer matrix is incontestably advantageous, as it is regioselective, where only the sulfo-EMCSactivated amino groups of chitosan will be able to react exclusively with the peptide Cys-side chain thiol groups. This offers an efficient and controlled attachment of the peptide with minimal, if any, perturbation of its bioactive sequence. In injected sample, after known dilutions of the original hydrolysate. c From the pexiganan-Ala-Ala-Cys amino acid sequence.
CONCLUSION
We have successfully achieved the synthesis (FT-IR and AAA) of a pexiganan-chitosan conjugate prepared by regioselective attachment of a Cys-containing pexiganan analog to the chitosan's amino groups. The conjugate will most probably find clinical application for topical treatment of infected diabetic foot ulcers and other skin injuries, as it combines the well-known antimicrobial potency of pexiganan with the remarkable properties of chitosan for bioadhesion and tissue regeneration. Results from ongoing biological studies toward this goal will be reported in due course.
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